Teleflex (TFX)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$138.36-1.14%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Broken: Primary pillar broken — EPS between $6.25 and $6.55 in 2026: FY26 EPS guidance $2.54-$2.84 vs target $6.25-$6.55.
Teleflex grows revenue about 14% to 15% in 2026. Profit per share is expected near $6.5. The company is investing in new products and returning cash to shareholders. Debt reduction and share buybacks improve financial health.
Revenue growth may slow below 8.5%. Profit margins could shrink due to cost pressures. Guidance cuts and mixed management progress raise risks.
The price is about 15% below our fair value near $156. Analysts expect 8.5% revenue growth. Our view is slightly more optimistic on growth and profit.
Breaks if: Debt reduction falls short of $800 million by end 2026
Deploy proceeds from strategic divestitures primarily to repurchase shares and reduce debt to enhance financial flexibility.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a mix of a durable compounder and a turnaround situation. The current thesis state is intact, with recent financial performance being strong, yet management execution remains volatile.
The market appears to have priced in a low expectations gap, suggesting that TFX is seen as relatively cheap compared to its peers. The valuation reflects a justified stance, indicating that investors are not overly optimistic about future growth.
Fundamentals are likely to show continued strength, given the recent earnings beat and strong revenue growth. However, management's mixed execution on guidance and strategic priorities introduces some uncertainty.
The thesis hinges on management's ability to execute on strategic divestitures and maintain revenue growth guidance. Additionally, the performance of sector bellwethers and broader economic conditions, such as job reports, will be crucial in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the outlook. Strategic divestitures in 2026 also reinforce confidence in revenue growth. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. The Company completed the OEM divestiture and used proceeds to pay off $700 million Term Loan A-2 and repurchased $250 million of stock in 2026-Q2. The $1 billion share repurchase program remains active with $750 million available. Management is delivering on capital allocation by reducing debt and repurchasing shares.
“Completed divestiture of OEM business; paid off $700 million Term Loan A-2; repurchased $250 million of common stock.”
“Committed to using majority of net proceeds from sales to return capital through $1 billion share repurchase and reduce debt by $800 million.”
“Remain committed to using majority of net proceeds from divestitures to return capital to shareholders through share repurchases and reduce debt.”
Breaks if: EPS falls below $6.25 in FY26
Breaks if: YoY revenue growth falls below 8.5% in FY26
Sustain pro forma adjusted constant currency revenue growth in the range of 3.5% to 5.5% for continuing operations in 2026.
Stated as a priority in 3 of last 3 quarters. Revenue growth guidance was maintained at 4.5% to 5.5% in 2025-Q4 and 2026-Q1, then reduced to 3.5% to 4.5% in 2026-Q2. Actual revenue grew 28.9% year-over-year in 2026-Q2, reflecting strong performance but management lowered guidance reflecting integration delays. The trajectory shows mixed delivery with a downward revision in guidance.
“Reducing GAAP revenue growth guidance range to 13.40% to 14.40%, pro forma adjusted constant currency revenue growth to 3.50% to 4.50%.”
“Maintaining pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%.”
“GAAP revenue growth guidance range of 14.40% to 15.40%, pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%.”
Breaks if: Divestitures not completed by end 2026-H2
Complete the divestiture of OEM, Acute Care, and Interventional Urology businesses to focus on core operations and strengthen financial flexibility.
Stated as a priority in 3 of last 3 quarters. The OEM divestiture was completed in 2026-Q2 for $1.5 billion with estimated after-tax proceeds of $1.25 billion. Management expects the remaining strategic divestitures to close in the second half of 2026. This priority is delivering with the OEM divestiture completed and other divestitures on track.
“Completion of the OEM divestiture marks a pivotal step in our transformation, enabling greater focus on our core businesses.”
“We continue to expect our two strategic divestitures to close in the second half of 2026.”
“We expect our two strategic divestitures to close in the second half of 2026 and remain committed to using net proceeds to return capital.”
Overall, TFX presents a complex picture with strong recent results but notable risks. Not investment advice.